RHB-107 - COVID-19

RHB-107, an investigation drug, is a proprietary, first-in-class, orally-administered potent inhibitor of several serine proteases, with antiviral and potential tissue-protective effects.

RHB-107 is a novel antiviral that targets human serine proteases involved in preparing the spike protein for viral entry into target cells. Because it is host-cell targeted, RHB-107 is expected to also be effective against emerging viral variants with mutations in the spike protein.

RHB-107 has demonstrated strong inhibition of SARS-CoV-2 viral replication in an in vitro human bronchial epithelial cell model.

RHB-107 has a strong clinical safety and biodistribution profile, demonstrated in previous clinical studies, including several Phase 1 and Phase 2 studies in different indications, in approximately 200 patients.

RHB 107

RHB-107 is being evaluated in an ongoing U.S. Phase 2/3 study for treatment of non-hospitalized patients with symptomatic COVID-19 who do not require supplemental oxygen. The study is a 2-part, multicenter, randomized, double-blind, placebo-controlled, parallel-group study that aims to enroll up to 310 patients.

The Phase 2/3 clinical study with RHB-107 in COVID-19 is registered on www.ClinicalTrials.gov, a web-based service by the U.S. National Institute of Health, which provides public access to information on publicly and privately supported clinical studies.